Postoperative Effects of Different Enterostomy Approaches
Study Details
Study Description
Brief Summary
Exploring the effect of protective ileostomy compared with transverse colostomy on the occurrence of complications, the occurrence of serious side effects of adjuvant chemotherapy and disease recurrence in patients with low rectal cancer after radical surgery from the perspective of intestinal microecology.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Low rectum refers to the rectal area <7 cm from the anal verge. At present, with the development of modern medical technology and the change of surgical concept, more and more patients can achieve the goal of radical treatment of low rectal cancer while preserving the anus. The occurrence of anastomotic leakage after anus-preserving surgery for low-grade rectal cancer is a more common and serious complication, with an incidence ranging from 2.4% to 15.9%, and the morbidity and mortality rate after anastomotic leakage can be as high as 16%.
A protective stoma protects the anastomosis by temporarily establishing an artificial channel above the anastomosis to divert feces and avoid mechanical pressure and contamination of the anastomosis by intestinal contents, allowing the anastomosis to grow and heal in relatively clean external conditions. The current choices of protective stoma sites are terminal ileum and transverse colon. Analysis of domestic and international studies shows that both protective transverse colostomy and ileostomy can achieve the effect of diversion of stool, but whether there is a difference in preventing anastomotic leakage and reducing adverse outcomes of anastomotic leakage remains to be investigated. There are significant inconsistencies between domestic and international studies regarding the incidence of stoma-related complications caused by different stoma sites: the study by Rondelli et al. showed that terminal ileostomy was associated with lower stoma-related complications, and a domestic meta-analysis recommended terminal ileostomy after radical rectal cancer surgery. In contrast, the study by the team from the Union Hospital showed that transverse colostomy was associated with significantly lower rates of stoma-related complications and perioperative complications of stoma reentry.
In addition, according to the Union Hospital team study, the incidence of postoperative intestinal microbiota dysbiosis was higher in patients who underwent ileostomy compared to those who underwent transverse colostomy. The total intestinal microbiota in the colon accounts for more than 90% of the systemic intestinal microbiota, and the intestinal microbiota in the large intestine can be roughly restored to preoperative levels after transverse colostomy, whereas a large amount of intestinal microbiota is lost and difficult to restore after ileostomy. The dominant flora in the colon, such as Clostridium and Enterococcus, are less likely to colonize the small intestine, which may adversely affect the intestinal and systemic immune regulation and antitumor immune effects of the body. In addition, patients with progressive low-grade rectal cancer routinely require adjuvant chemotherapy after radical surgery, and there are no studies at domestic or abroad on whether terminal ileostomy, which is more common than transverse colostomy for intestinal dysbiosis, has any differences on the efficacy and toxic side effects of adjuvant chemotherapy for patients; furthermore, it is also important to investigate whether the two different stoma methods have an impact on long-term disease recurrence and overall survival of patients. In addition, whether the two different stoma modalities have an effect on long-term disease recurrence and overall survival is also an important research question.
Therefore, the investigators propose to conduct a prospective, randomized, controlled study in patients with low-grade rectal cancer who underwent radical surgery (with or without neoadjuvant radiotherapy) to investigate whether there are differences in the incidence of complications, serious side effects of adjuvant chemotherapy, and disease recurrence after terminal ileostomy versus transverse colostomy from the perspective of intestinal microecology, and to explore the differences in systemic immunity, inflammatory, and metabolic status.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Ileostomy Protective ileostomy as a defunction mean after low anterior resection |
Procedure: Ileostomy
Protective loop ileostomy after low anterior resection
|
| Experimental: Transverse colostomy Protective transverse colostomy as a defunction mean after low anterior resection |
Procedure: Transverse colostomy
Protective loop transverse colostomy after low anterior resection
|
Outcome Measures
Primary Outcome Measures
- Microbiome functional gene capacity in postoperative stoma pouch and distal intestine by metagenomic sequencing [1 month]
Determining the structural impact of different stoma methods on intestinal microecology by metagenomic sequencing
- Microbiome functional gene capacity in postoperative stoma pouch and distal intestine by metagenomic sequencing [6 months]
Determining the structural impact of different stoma methods on intestinal microecology by metagenomic sequencing
- Microbiome functional gene capacity in postoperative stoma pouch and distal intestine by metagenomic sequencing [3 years]
Determining the structural impact of different stoma methods on intestinal microecology by metagenomic sequencing
Secondary Outcome Measures
- Concentration of inflammatory markers [1 month]
Measurement of plasma inflammatory markers such as IL-6, TNF-α, CRP and PCT
- Changes in cellular immunity status [1 month]
Estimation of dynamics of cellular immunity as measured by the proportion of CD3+, CD4+, CD8+, CD4+CD25+CD127low, CD16+CD56+ cells using flowcytometry
- Changes in humoral immunity status [1 month]
Estimation of dynamics of humoral immunity as measured by the proportion of CD3-CD19+, CD20+ cells using flowcytometry
- Incidence of anastomotic leakage [1 month]
The occurrence of postoperative anastomotic leakage
- Early postoperative complications rate [1 month]
Incidence of postoperative complications such as diarrhea, intestinal obstruction, incisional infection, stoma prolapse, stoma necrosis, parastomal hernia, irritant dermatitis, renal insufficiency, etc.
- First intestinal gas time [1 month]
Documenting the patient's post-operative recovery
- First defecation time [1 month]
Documenting the patient's post-operative recovery
- Concentration of inflammatory markers [6 month]
Measurement of plasma inflammatory markers such as IL-6, TNF-α, CRP and PCT
- Changes in cellular immunity status [6 month]
Estimation of dynamics of cellular immunity as measured by the proportion of CD3+, CD4+, CD8+, CD4+CD25+CD127low, CD16+CD56+ cells using flowcytometry
- Changes in humoral immunity status [6 month]
Estimation of dynamics of humoral immunity as measured by the proportion of CD3-CD19+, CD20+ cells using flowcytometry
- Incidence of grade 3-4 serious side effects of adjuvant chemotherapy [6 month]
Assessed with Common Terminology Criteria for Adverse Events (CTCAE) v5.0
- Adjuvant chemotherapy toxicity and quality of life scores [6 months]
Assessed with European Organization for Research and Treatment of Cancer high-dose chemotherapy specific quality of life questionnaire module (EORTC QLQ-HDC29), ranging from 29 to 116 and higher scores suggest worse quality of life
- Concentration of inflammatory markers [3 years]
Measurement of plasma inflammatory markers such as IL-6, TNF-α, CRP and PCT
- Changes in cellular immunity status [3 years]
Estimation of dynamics of cellular immunity as measured by the proportion of CD3+, CD4+, CD8+, CD4+CD25+CD127low, CD16+CD56+ cells using flowcytometry
- Changes in humoral immunity status [3 years]
Estimation of dynamics of humoral immunity as measured by the proportion of CD3-CD19+, CD20+ cells using flowcytometry
- Disease-free Survival [3 years]
Time between the start of surgical randomization and recurrence of disease or death (from any cause)Time between the start of surgical randomization and recurrence of disease or death (from any cause)
- Overall Survival [3 years]
Time from the start of surgical randomization to death (from any cause)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Pathological confirmed adenocarcinoma of the rectum;
-
Patients age between 18-80;
-
Baseline AJCC stage I-III: cT1-4N0-2M0 (AJCC-8 version);
-
Eastern Cooperative Oncology Group (ECOG) physical status score of 0 to 2;
-
Patients voluntarily sign informed consent.
Exclusion Criteria:
-
Other types of rectal cancer (adenosquamous carcinoma, squamous carcinoma, neuroendocrine tumors, clear cell carcinoma, spindle cell carcinoma, undifferentiated carcinoma);
-
Combination of rectal cancer with multiple carcinomas;
-
Pre-operative presence of acute and chronic infectious diseases or foci of infection;
-
Intraoperative radical surgery was not performed for various reasons；
-
Colostomy was not performed at the same time as the radical rectal cancer surgery;
-
Combined with intestinal obstruction, intestinal perforation, intestinal bleeding, peritonitis, etc. requiring emergency surgery;
-
Metastatic cancer;
-
Serious heart, lung, liver and kidney disease, can not tolerate surgery;
-
Active liver disease or abnormal liver function with ALT, AST and TBIL more than 2 times the upper limit of normal values;
-
Renal impairment with Cr ≥ 2 times the upper limit of normal or BUN ≥ 2 times the upper limit of normal;
-
Blood leukocytes below the lower limit of normal value, or platelets below the lower limit of normal value, or with other blood system diseases;
-
Pregnancy;
-
Mental illness or serious intellectual disability who cannot describe their feelings correctly;
-
Severe coagulation disorder, bleeding tendency;
-
Patients with severe uncontrolled medical disease, recent history of myocardial infarction (within 3 months), uncontrolled severe hypertension and severe diabetes mellitus;
-
Patients need to be on antibiotics/other probiotics for a long time.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Fudan University Shanghai Cancer Center | Shanghai | China | 200032 |
Sponsors and Collaborators
- Fudan University
Investigators
- Principal Investigator: Yanlei Ma, PhD, Fudan University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- FDCRC88-MYL